Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

14 treatments under study, led by Training Group

Research Leaders

20 sponsors active, led by University Hospital, Clermont-Ferrand

Related Conditions

Often studied with 18 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 12 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (4)
Phase 2 (2)
Phase 4 (2)

Trial Status

Completed6
Unknown4
Enrolling By Invitation1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06498349Not ApplicableRecruiting

Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

NCT06923865Not ApplicableEnrolling By Invitation

Controlled Evaluation of an Exercise Program for Overweight Adolescents

NCT03887429Phase 2CompletedPrimary

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

NCT03970239Not ApplicableUnknown

Serotonin in Impulse Control Disorders in Parkinson's Disease

NCT02722174CompletedPrimary

Fingerprinting of Impulsivity

NCT02755181CompletedPrimary

fMRI in Impulsivity

NCT02319395Completed

Behavioural Addiction and Genetics in Parkinson's Disease

NCT02934919Phase 2UnknownPrimary

Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study

NCT02796040Not ApplicableUnknown

Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.

NCT01354236Unknown

Mental Health Related to School Dropout in Luxembourg

NCT00115011Phase 4CompletedPrimary

Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00118014Phase 4CompletedPrimary

Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania

Showing all 12 trials

Research Network

Common Treatments

  • Training Group1
  • Bilateral High Frequency Deep Brainstimulation Of The Subthalamic Nucleus Combined With Best Medical Treatment1
  • Escitalopram1
  • Mri1
  • Habit Reversal Training1

Active Sponsors

  • University Hospital, Clermont-Ferrand2
  • Massachusetts General Hospital2
  • Boehringer Ingelheim2
  • Public Research Centre Health, Luxembourg1
  • Pfizer1

Top Investigators

Related Conditions

  • Parkinson Disease4
  • Quality Of Life1
  • Program Evaluation1
  • Health Promotion1
  • Mood Disorders1

Activity Timeline